Novel compound iron metabolism mutants were also phenotypically characterized here for the first time. We demonstrate that serum hepcidin concentrations correlate with liver hepcidin mRNA expression, transferrin saturation and non-heme liver iron. In some circumstances, serum hepcidin-1 more accurately predicts iron parameters than hepcidin mRNA, and distinguishes smaller, statistically significant differences between experimental groups.
Introduction
Hepcidin (Hepc) is a 25-amino-acid cysteine-rich peptide first described in human blood and urine.
1,2 Hepcidin expression is induced by iron loading and inflammation and suppressed by anemia and hypoxia. [3] [4] [5] Iron-dependent regulation of hepatocyte hepcidin expression requires multiple proteins that together "sense" plasma transferrin-bound iron and transmit a bone morphogenetic protein (BMP)-dependent signal to increase hepcidin gene transcription. 6 The predominant physiological role of hepcidin is to regulate cellular iron egress through the iron exporter ferroportin (FPN1) present on the surface of macrophages of the reticuloendothelial system, duodenal enterocytes and hepatocytes [7] [8] [9] . Hepcidin binds FPN1, causing its internalization and degradation. 10 By this mechanism, hepcidin regulates the absorption of dietary iron via duodenal enterocytes and recycling of hemoglobin-derived iron in macrophages.
While most mammals including humans, sheep, 11 dogs, 12 and horses 11 have a single hepcidin gene, mice have two: Hepc-1 and Hepc-2. 3 Hepc-2 expression responds to iron, 13 but does not appear to regulate iron metabolism, in contrast to Hepc-1, as transgenic overexpression of Hepc-2 does not lead to an iron-related phenotype. 14, 15 Due to its small, compact structure and poor immunogenicity, quantitative immunoassays for hepcidin have been difficult to develop. The current standard method to evaluate Hepc-1 expression in mice is quantitation of liver mRNA transcripts by RT-PCR (qPCR). An assay for
Hepc-1 protein in small quantities of plasma and urine would permit a more dynamic understanding of its biology in research and pre-clinical murine models by accurately quantifying the biologically active hepcidin hormone itself and allowing serial measurements in a single animal over time. While mass spectrometry (MS) protocols for mouse Hepc-1 quantitation have recently been described, 16, 17 there is no assay that is both widely accessible and validated in diverse experimental models. Here we describe a competitive enzyme linked immunosorbent assay (C-ELISA) that sensitively and specifically measures murine serum and urine Hepc-1. We compare the Hepc-1 C-ELISA to qPCR assays in three settings: 1) experimental manipulation of dietary iron, anemia and inflammation, 2) previously described transgenic models of iron overload and iron deficiency, and 3) novel compound mutant transgenic mice. We not only demonstrate that Hepc-1 can be analyzed reliably in small volumes, permitting serial sampling of individual mice, but that the C-ELISA correlates better with iron-related phenotypes and, in some cases, its higher accuracy at lower concentrations permits statistically significant differences to be discerned in small datasets.
Methods

Mouse Hepcidin-1 ELISA
Antibodies to mouse Hepc-1 were prepared similarly to a previously described approach (Supplementary Materials and Methods).
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Effect of dietary iron
Serum samples were collected from three groups of 5-week old C57BL/6 male and female mice (n = 8 per gender, per diet; n = 48 total) fed a low iron diet (4ppm), normal iron diet (300ppm), or high iron diet (30,000ppm; Harlan Teklad Custom Diets) over the previous 4 weeks. Serum samples were frozen at -80°C until analysis.
Effect of Acute Blood Loss
Six-week old C57BL/6 male and female mice (n = 6 per gender, n = 12 total) were maintained on 20ppm low iron diet for 12 days after introduction to the vivarium. Urine was collected and mice were bled at baseline via the mandibular vein (≤200µl). Mice were returned to 20ppm diet until a second urine and blood sample (50µl) was collected 72hr later. Serum was prepared and stored at -80°C until analysis.
Effect of Inflammation
The same group of C57BL/6 animals employed in the phlebotomy experiment described above (8 weeks old) were divided into two groups of male and female mice (n = 3 per gender per group, n = 12). The experimental group was treated with lipopolysaccharide (LPS, Escherichia coli O111:B4; Sigma) by intraperitoneal injection (1µg LPS/g body weight). 18 Controls (n = 3 per gender) were treated with PBS. Blood and urine samples (50µl) were collected after dietary acclimation at baseline before LPS injection and at 24hr post-treatment.
Animal Husbandry and Transgenic mouse models
All procedures were performed in accordance with protocols approved by the respective Institutional Animal Care and Use Committees (See Supplementary Materials and Methods).
Statistics
For all datasets, two-tailed Student's t-test (Microsoft Excel) with P<0.05 was employed to determine significance.
Results
Antibody Specificity
We produced high-titer polyclonal antisera against mouse Hepc-1 and employed the Protein A purified fraction to develop a competitive ELISA (C-ELISA). Western blot analysis demonstrated that the antibodies bind both synthetic Hepc-1 and a novel synthetic Hepc-1-biotin conjugate (Peptides International, Louisville, KY) employed in the C-ELISA with equal affinity (Supplemental Figure 1) .
The murine genome contains a second hepcidin gene, Hepc-2, which encodes a protein with 68% amino acid identity. 14 To determine specificity of the antibodies, we tested the ability of Hepc-1 and Hepc-2 to compete in solution with the Hepc-1 biotin conjugate in the C-ELISA assay. We detected no interaction, even at a Hepc-2 concentration of 1000 ng/ml ( Figure 1A ).
We also assessed the cross-reactivity of rat hepcidin, which is 80% identical to mouse Hepc-1, and found no response at concentrations up to 250 ng/ml, and only a slight response beyond that, up to 1000 ng/ml. Anti-Hepc-1 antibodies also did not bind to human hepcidin-25. This lack of crossreactivity enabled us to employ human plasma or urine spiked with mouse Hepc-1 to assess performance of the assay.
C-ELISA performance
Standard curves were generated with 12 or 8 calibration points beginning at 1000 ng/ml and proceeding lower by serial 1:2 or 1:3 dilutions, respectively. The 12-point curve was used to evaluate the initial assay characteristics, including specificity (Figure 1 ), but all subsequent data utilized an 8-point curve. This standard was acceptable according to criteria outlined in DeSilva et al, 19 insofar as the accumulated back-calculated values from all curves have an absolute mean relative error (RE) ≤ 10% and a coefficient of variation (CV) ≤15% (Table 1 ). The lower limit of detection (LLOD) of synthetic hepcidin in the standard curve (defined by two standard deviations (SD) above the zero standard) was 0.18 ng/ml, and the dynamic range of the assay extends to 333 ng/ml with an average half-maximal effective concentration (EC 50 ) of 3.3 ng/ml (Table 1 ). The LLOD for the C-ELISA is 3.6 ng/ml (1.3 nmol/L) and 1.8 ng/ml (0.065 nmol/L) and the lower limit of quantitation (LLOQ) is 10.3 ng/ml (3.7 nmol/L) and 5.1 ng/ml (1.86 nmol/L) for 5% and 10% serum dilutions, respectively. Similarly, five SD above the zero standard defines the derived LLOQ for 5% and 10% serum dilutions. The upper limit of quantitation of the C-ELISA was (ULOQ) 6666 ng/ml (2418 nmol/L) and 3333 ng/ml (1209 nmol/L), for 5% and 10% serum dilutions, respectively.
Five-percent human serum spiked with murine Hepc-1 gave an average recovery of 100%
(range = 93-107%) across the range of the standard curve (n = 4). Similarly, in Hepc-1-spiked 10% human urine, we observed an average percent recovery of 99% (range = 93-105%) demonstrating minimal interference (n = 3). Recovery in 10% serum gave slight interference, manifested only at <4 ng/ml, as evidenced by a 30-40% over-recovery of Hepc-1 in spiked samples (data not shown).
Precision was determined by assaying human serum spiked with Hepc-1. The average intraassay CV was 3.1% (range = 1.3-5.2%; n = 4). The average inter-assay precision of these samples (n = 4 independent assays) was 5.9% (range = 4.7-7.7%). Similarly, human urine spiked with Hepc-1 was analyzed, and yielded an average intra-assay CV of 5.5% (range = 1.0-11.7%; n = 3), and an average inter-assay CV (n = 3) of 3.5% ranging from 1.5% to 5.9%.
Assay linearity was also tested in human serum and urine spiked with 1000 ng/ml Hepc-1 diluted 1:4, 1:8, or 1:16 in buffer (n = 3 each). Average recovery was 94% (range 92-95%) and 108% (range 107-112%) in serum and urine, respectively.
Serum Hepc-1 response to dietary iron correlates with hepatic hepcidin mRNA expression Serum Hepc-1, ferritin, and iron parameters were determined in male and female mice fed low (4ppm), normal (300ppm), and high (30,000ppm) iron diets (n = 8 for each sex and diet). As expected, we found that serum Hepc-1, iron, transferrin saturation and ferritin increased in parallel with increasing dietary iron ( Figure 1B , Table 2 ). Only in mice fed the 300ppm diet was there a statistically significant difference between serum hepcidin levels between male and female animals (Table 2, Figure 1B ). Plasma iron and transferrin saturation were significantly different between genders in mice fed normal and high iron diets ( Figure 1B , Supplemental Figure 2B ), while ferritin was significant between genders in mice fed low and high iron diets ( Figure 1B ). Combining data for both genders and all iron diets, there was a strong (r = 0.881) linear correlation between log 10 [Hepc-1] and transferrin saturation (Supplemental Figure 2C ). In all mice subjected to dietary iron modulation, serum Hepc-1 and liver mRNA expression were highly correlated (r = 0.889, Figure 1C , Supplemental Figure 1A ).
Correlation of serum hepcidin to urinary hepcidin
In the absence of a reliable assay for murine Hepc-1, it has been impossible to determine whether in mice, as in humans, [20] [21] [22] urinary and serum hepcidin are correlated. To answer this question, serial serum and urine samples were collected from male and female mice on days 9, 12, 13, and 14 (n=6 per day; 14 males and 10 females; n=24 total) as they acclimated to a low iron diet (20ppm). We found a moderate correlation (r = 0.688) between serum hepcidin and urinary hepcidin normalized to urinary creatinine (Supplemental Figure 2D ).
The effects of acute blood loss and inflammation
Liver Hepc-1 mRNA abundance decreases in response to anemia. 4 Following acclimation to a low iron diet (20ppm), we induced acute anemia by bleeding male and female mice (n = 3 per gender). Hepc-1 was measured in serum and urine from the initial bleed and again 3 days later.
As expected, we found that serum and urinary hepcidin were suppressed 2.3-to 3.6-fold, respectively ( Figure 1D ).
Hepcidin is a type II acute-phase protein induced by the inflammatory cytokine, IL-6. 5 In order to mimic acute inflammation, groups of male and female mice were injected intraperitoneally with PBS or LPS at 1µg/g body weight. 18 Serum and urine Hepc-1 were measured immediately prior to injection and again 24hr later ( Figure 1E ). In both males and females, serum and urine Hepc-1 concentrations dramatically increased 24hr after exposure to LPS. For serum hepcidin, the average increase was 46-fold in males and 20-fold in females, and for urine Hepc-1 the average increase was 26-fold in both genders.
Comprehensive re-analysis of genetic mouse models of dysregulated iron homeostasis with the Hepc-1 C-ELISA
In order to further validate the murine Hepc-1 C-ELISA assay, we compared its performance to qPCR of liver RNA by re-analyzing previously published cohorts of animals with genetic iron disorders. We evaluated serum hepcidin in the Trf hpx/hpx mouse model of hypotransferrinemia, which has profound iron overload due to a near complete absence of transferrin and severely suppressed hepcidin. 23, 24 We also studied animals lacking the transmembrane serine protease Tmprss6, which are iron deficient due to overexpression of hepcidin. [25] [26] [27] [28] [29] [30] In Trf hpx/hpx animals we found serum concentrations of hepcidin (14.98 ± 2.0 ng/ml) at least 10-fold lower than in wildtype animals ( Figure 2A ). In contrast, despite their iron deficiency, Tmprss6 -/-mice have hepcidin concentrations two-fold that of normal ( Figure 2C ). Animals heterozygous for a Figure 2G ). 32 We evaluated serum hepcidin in the Hbb th3/+ model of thalassemia intermedia and the Hfe -/-model of hereditary hemochromatosis. In both cases, hepcidin measured by qPCR is suppressed relative to the extent of systemic iron overload. 33 We also examined serum hepcidin in each of these mutant strains following treatment with a lipid nanoparticle encapsulated siRNA directed against Tmprss6, which ameliorates the thalassemia and hemochromatosis iron and anemia phenotypes. 33 We confirmed inappropriately low levels of serum hepcidin in iron-loaded mutants and induction of hepcidin by Tmprss6 siRNA treatment ( Figures 3A, 3C ). By and large, in these and previous analyses of Trf hpx/hpx and Tmprss6 -/-animals, the correlation between qPCR and serum Hepc-1 analyses is strong ( Figures 2B, 2D , 2H, 3B, 3D). Please note that
Pearson correlation coefficients for each genetic cohort analyzed individually may be found in Supplementary Table 1 .
We also re-examined hepcidin in a Tfr2 -/-model of hereditary hemochromatosis, 34 in wild type animals overexpressing a liver-specific Hfe-transgene, 35 and in Tfr2 -/-animals carrying that same transgene. The latter two models are iron deficient, owing to Hfe-induced hepcidin overexpression. In contrast to experiments performed on inbred genetic backgrounds, in these crosses, the serum hepcidin-mRNA correlation was not as robust ( Figure 3E-F) . Importantly, correlation of transferrin saturation ( Figure 3G ) and the non-heme liver iron ( Figure 3H ) with hepcidin measured by C-ELISA was far better than with hepcidin measured by qPCR. This suggests that serum hepcidin may be more indicative of iron-related biological outcomes.
Serum hepcidin in novel compound mutant genetic mouse models of dysregulated iron metabolism.
Previously, we and others have proposed a model whereby HFE bound to TFRC in hepatocytes participates in regulating hepcidin production in response to plasma iron. 36 In this model, as saturation rises, and total body iron burden increases, diferric transferrin (Tf- It has been postulated that HFE and TFR2 also function in a complex with HJV, a BMP coreceptor, to modulate hepcidin expression in relation to serum transferrin saturation 37 Tfr2, or both genes had significantly elevated transferrin saturations and non-heme liver iron, as well as decreased non-heme spleen iron ( Figures 5A-C) , congruent with the low hepcidin expression in both qPCR and C-ELISA assays we observed ( Figures 5D-F) . Importantly, a statistically significant difference between animals lacking Tfr2, Hjv or both proteins was detected only with the serum assay, possibly, once again, due to inherent variability in the qPCR-based assay. Furthermore, serum hepcidin correlated better than qPCR with transferrin saturation ( Figure 5G ) and non-heme liver iron ( Figure 5H ). Likely reflective of their fully replete iron status, mice lacking Tfr2, Hjv or both proteins had significantly elevated hemoglobin, hematocrit, and MCV compared to WT animals (Supplemental Figures 4A-C) . Interestingly, the MCV was disproportionately increased in Tfr2 -/-mice, possibly relating to its proposed intrinsic effect on erythropoiesis. 6 As expected, in animals lacking HFE or HJV or both proteins, transferrin saturation and liver non-heme iron were greatly increased ( Figures 6A and 6B) , while non-heme spleen iron was decreased ( Figure 6C ). Commensurate with the smaller decrease in serum hepcidin ( Figure 
Discussion
We have developed and comprehensively validated a sensitive, robust C-ELISA to accurately measure serum Hepc-1 in 2.5-10.0 µ l of murine serum and urine with no cross-reactivity with mouse Hepc-2. The assay has high sensitivity with a LLOD of 3.6 ng/ml and a wide dynamic range-up to 6666 ng/ml using a 5µl serum sample (5% serum). With 5% serum and urine, mean recovery of spiked synthetic Hepc-1 peptide was 100% and 99% (range 93-107%), respectively. Spike recovery of synthetic Hepc-1 in 5% serum yielded an average recovery of 93% at a serum hepcidin concentration of 1.4 ng/ml. Decreasing sample volume to 2.5% decreased sensitivity of the assay at the lowest concentrations (LLOD 7.2ng/ml), while 10% serum greatly increased assay sensitivity (LLOD 1.8ng/ml) but introduced some interference that affected spike recovery below 4ng/ml. The C-ELISA allows accurate, linear Hepc-1 quantitation in a range of sample volumes with five percent serum being optimal.
In both serum and urine, the average CVs of precision were under 6%, an accepted norm for diagnostic assays. 19 Although we have not systematically assessed plasma as a substrate, based on past experience with comparable human C-ELISA data and limited preliminary data, the assay should perform well in lithium heparin prepared plasma (TBB, unpublished).
Nevertheless, we will have to evaluate this biological matrix more systematically. The results from murine models across a broad range of murine models exhibiting dysregulated iron homeostasis, demonstrate that the C-ELISA is sensitive and robust with a broad reportable range in singleton assays employing 5% serum or urine (i.e., 1:20 dilutions). The small sample volumes of serum or urine required for hepcidin measurement using the C-ELISA permits serial sampling with minimal secondary physiological effects, enabling true longitudinal assessment of individual mice, and reducing the numbers of animals required to perform experiments examining serum hepcidin concentrations over hours or months of time. This also has the important added benefit for pre-clinical research of mitigating the biological variability inherent in current "longitudinal" pPCR experiments involving cohorts of killed at serial time points for liver mRNA.
At present, the standard method to report changes in hepcidin expression relies on qRT-PCR of liver extracts. 13 Similar to the C-ELISA, MS measurements from mouse 17 and human tissue culture cells, 38 have shown high degrees of correlation with liver transcripts. However, contrary to our observations, in these mouse studies, there was no correlation to serum iron.
Furthermore, one MS assay failed to detect Hepc-1 in mouse urine. 39 In contrast, our C-ELISA clearly demonstrates Hepc-1 present in murine urine under steady state and pro-inflammatory conditions. It is possible that pre-analytical peptide enrichment steps required for the MS assay may selectively isolate Hepc-1 or Hepc-2 in a matrix-dependent manner. 17 As such, this is the first report of concordance between murine serum and urine Hepc-1 levels, comparable to that observed by using C-ELISA 20 or MS methodologies in humans. 21, 22 Overall, we observed a correlation coefficient of r = 0.69 for serum and urine Hepc-1 from combined gender sample sets. Taken separately, male and female mice also had similar degrees of correlation (data not shown). However, a more complete understanding of effects of gender and genetic background is required to fully understand the interplay between serum and urinary hepcidin, an avenue of inquiry now easily permitted by the availability of this assay.
Using this assay, we have reaffirmed several key principles of hepcidin regulation in mice based purely on mRNA expression data. For example, changes in erythropoietic activity have been shown to modulate liver hepcidin mRNA expression during anemia in an erythropoietin-and bone marrow activity-dependent manner. [40] [41] [42] Phlebotomy induced acute anemia reduced Hepc-1 liver mRNA. 4 Concordant with these data, our immunoassay measured a 2.3-to 3.6-fold decrease in Hepc-1 in males and females, in serum and urine three days after blood collection. comparison of serum hepcidin to both transferrin saturation and non-heme liver iron reveals a close correlation between hepcidin production and metrics of iron metabolism; correlations between qPCR of liver hepcidin mRNA and these parameters are less informative. Taken together, these retrospective analyses demonstrate that this hepcidin C-ELISA is a more sensitive, accurate and precise method that permits the distinction of finer differences in serum hepcidin concentrations otherwise not detected by mRNA expression analyses.
In support of the prevailing hypothesis that Tf-Fe 2 displaces HFE from TFRC to positively regulate hepcidin expression, we previously demonstrated that mutations in TFRC leading to constitutive association with or disassociation from HFE lead to hepcidin-related iron overload and anemia, due to hepcidin suppression or expression, respectively. 36 Similarly, we demonstrate that loss of one allele of Tfrc leads to elevated serum hepcidin and RBC parameters compatible with cellular iron deficiency. Whether this is a primary defect in hepatocellular hepcidin regulation or a secondary effect from defective RBC precursor iron uptake (or a combination of both), is uncertain. However, since concomitant homozygous loss of HFE and heterozygous loss of TFRC (Hfe -/-Tfrc +/-genotype), leads to iron overload and similarly iron deficient RBC parameters and anemia, at least part of the effect is intrinsic to the RBC precursor.
Furthermore, it has been postulated that HFE and TFR2 function in a complex with HJV to modulate hepcidin expression. 37 To explore the interrelationship of HJV, HFE and TFR2 with hepatic hepcidin expression, we bred Tfr2 -/-and Hfe -/-lines to Hjv -/-animals. We reaffirmed the finding that loss of HJV leads to greatly diminished hepcidin expression and iron overload.
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More importantly, we show here that loss of Hfe or Tfr2 in combination with loss of Hjv, does not make the iron loading phenotype more severe, further cementing the hypothesis that HFE and TFR2 function upstream of HJV to regulate hepcidin expression, and subsequently, iron metabolism. We clearly showed a significant decrease of serum hepcidin in Tfr2 -/-Hjv -/-double nulls compared to Tfr2 -/-single null animals using this C-ELISA assay that was not observed by qPCR. These data collectively demonstrate the value of assessing serum hepcidin with this C-ELISA compared to qPCR. The C-ELISA can distinguish small differences in hepcidin mRNA expression by detecting low nanogram concentrations and changes in Hepc-1, permitting more subtle interpretations of results in mouse models of hepcidin dysregulation.
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